Maxigesic approval positive for AFT Pharmaceuticals

Maxigesic approval positive for AFT Pharmaceuticals
AFT founder and managing director Hartley Atkinson. (Image: Supplied)
Tamara Poi-Ngawhika
 AFT Pharmaceuticals, the owner of Maxigesic, offers investors a “large opportunity but with a high degree of uncertainty”, according to Forsyth Barr analysts.The New Zealand stock exchange-listed company has just announced its rapid-release tablet form of Maxigesic has been granted approval by the United States Food and Drug Administration (FDA) for use in the country.Breaking into the US market is difficult because getting FDA approval can be challenging. AFT said the US market is worth about US$7.16 billion (NZ$11.5b) and is...

More Markets

Transpower cautious over hydro lake level rule changes
Markets

Transpower cautious over hydro lake level rule changes

Transpower can authorise hydro lakes to dip further.

Why this tech firm sees a Trump tariff opportunity
Markets The small cap wrap

Why this tech firm sees a Trump tariff opportunity

Plus IkeGPS' wins in the US, Trade Window targets trade war, TruScreen, and more.

US stocks surge on hopes of China trade deal
Markets

US stocks surge on hopes of China trade deal

Asian indexes closed mixed, while oil prices firmed.

AFP 9:30am
Fast-food sector in 'consolidation' stage: IbisWorld
Retail

Fast-food sector in 'consolidation' stage: IbisWorld

Higher costs are helping McDonald’s and KFC grab market share.